ValuEngine upgraded shares of Microbot Medical (NASDAQ:MBOT) from a hold rating to a buy rating in a report published on Thursday.
Separately, Zacks Investment Research cut Microbot Medical from a hold rating to a sell rating in a research report on Wednesday, August 29th.
MBOT stock traded up $0.39 during trading on Thursday, hitting $6.64. 46,439 shares of the company traded hands, compared to its average volume of 20,836. Microbot Medical has a 1 year low of $6.05 and a 1 year high of $22.80.
Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04). equities analysts predict that Microbot Medical will post -2.4 earnings per share for the current year.
About Microbot Medical
Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.
Featured Article: Google Finance Portfolio
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.